Salivary Gland Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Salivary Gland Cancer – Pipeline Review, H2 2016’, provides an overview of the Salivary Gland Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Salivary Gland Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Salivary Gland Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Salivary Gland Cancer

The report reviews pipeline therapeutics for Salivary Gland Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Salivary Gland Cancer therapeutics and enlists all their major and minor projects

The report assesses Salivary Gland Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Salivary Gland Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Salivary Gland Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Salivary Gland Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bayer AG

Ignyta, Inc.

Johnson & Johnson

Loxo Oncology, Inc.

Merck & Co., Inc.

Plexxikon Inc.

Taiwan Liposome Company, Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Salivary Gland Cancer Overview 6

Therapeutics Development 7

Pipeline Products for Salivary Gland Cancer - Overview 7

Pipeline Products for Salivary Gland Cancer - Comparative Analysis 8

Salivary Gland Cancer - Therapeutics under Development by Companies 9

Salivary Gland Cancer - Therapeutics under Investigation by Universities/Institutes 10

Salivary Gland Cancer - Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Salivary Gland Cancer - Products under Development by Companies 13

Salivary Gland Cancer - Products under Investigation by Universities/Institutes 14

Salivary Gland Cancer - Companies Involved in Therapeutics Development 15

Bayer AG 15

Ignyta, Inc. 16

Johnson & Johnson 17

Loxo Oncology, Inc. 18

Merck & Co., Inc. 19

Plexxikon Inc. 20

Taiwan Liposome Company, Ltd. 21

Salivary Gland Cancer - Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

Cellular Immunotherapy for Oncology - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

entrectinib - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

LOXO-101 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

pembrolizumab - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

pexidartinib - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

regorafenib - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

tipifarnib - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

TLC-388 - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

Vaccine to Target WT1 for Oncology - Drug Profile 100

Product Description 100

Mechanism Of Action 100

R&D Progress 100

Salivary Gland Cancer - Dormant Projects 101

Salivary Gland Cancer - Discontinued Products 102

Appendix 103

Methodology 103

Coverage 103

Secondary Research 103

Primary Research 103

Expert Panel Validation 103

Contact Us 103

Disclaimer 104

List of Tables

List of Tables

Number of Products under Development for Salivary Gland Cancer, H2 2016 7

Number of Products under Development for Salivary Gland Cancer – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Salivary Gland Cancer – Pipeline by Bayer AG, H2 2016 15

Salivary Gland Cancer – Pipeline by Ignyta, Inc., H2 2016 16

Salivary Gland Cancer – Pipeline by Johnson & Johnson, H2 2016 17

Salivary Gland Cancer – Pipeline by Loxo Oncology, Inc., H2 2016 18

Salivary Gland Cancer – Pipeline by Merck & Co., Inc., H2 2016 19

Salivary Gland Cancer – Pipeline by Plexxikon Inc., H2 2016 20

Salivary Gland Cancer – Pipeline by Taiwan Liposome Company, Ltd., H2 2016 21

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Stage and Target, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 26

Number of Products by Stage and Route of Administration, H2 2016 28

Number of Products by Stage and Molecule Type, H2 2016 30

Salivary Gland Cancer – Dormant Projects, H2 2016 101

Salivary Gland Cancer – Discontinued Products, H2 2016 102

List of Figures

List of Figures

Number of Products under Development for Salivary Gland Cancer, H2 2016 7

Number of Products under Development for Salivary Gland Cancer – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 12

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Top 10 Targets, H2 2016 23

Number of Products by Stage and Top 10 Targets, H2 2016 23

Number of Products by Top 10 Mechanism of Actions, H2 2016 25

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 25

Number of Products by Routes of Administration, H2 2016 27

Number of Products by Stage and Routes of Administration, H2 2016 27

Number of Products by Molecule Types, H2 2016 29

Number of Products by Stage and Molecule Types, H2 2016 29

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports